Far-infrared radiation prevents decline in β-cell mass and function in diabetic mice via the mitochondria-mediated Sirtuin1 pathway

June 8, 2025

Abstract

Insulin deficiency in type 2 diabetesmellitus (DM) involves a decline in both pancreatic β-cellmass and function. Enhancing β-cell preservation represents an important therapeutic strategy to treat type 2 DM. Far-infrared (FIR) radiation has been found to induce promyelocytic leukemia zinc finger protein (PLZF) activation to protect the vascular endothelium in diabetic mice. The influence of FIR on β-cell preservation is unknown. Our previous study reveals that the biologically effective wavelength of FIR is 8–10 μm. In the present study, we investigated the biological effects of FIR (8–10 μm) on both survival and insulin secretion function of β-cells. FIR reduced pancreatic islets loss and increased insulin secretion in nicotinamide-streptozotocin-inducedDMmice, but only promoted insulin secretion in DM PLZF−/− mice. FIR-upregulated PLZF to induce an anti-apoptotic effect in a β cell line RIN-m5f. FIR also upregulated mitochondrial function and the ratio of NAD+/NADH, and then induced Sirtuin1 (Sirt1) expression. The mitochondria Complex I inhibitor rotenone blocked FIR-induced PLZF and Sirt1. The Sirt1 inhibitor EX527 and Sirt1 siRNA inhibited FIR-induced PLZF and insulin respectively. Sirt1 upregulation also increased CaV1.2 expression and calcium influx that promotes insulin secretion in β-cells. In summary, FIR-enhanced mitochondrial function prevents β-cell apoptosis and enhances insulin secretion in DM mice through the Sirt1 pathway.

- Metabolism Clinical and Experimental 104 (2020) 154143

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIRAPY was showcased at ERA 2025 in Vienna, where we reconnected with partners and met new potential

FIRAPY Showcased at ERA 2025 in Vienna

June 8, 2025
FIRAPY Medical was honored to exhibit at ERA 2025 , held at Austria Center Vienna from June 4–7, 2025 . This event marked FIRAPY’s first return to the ERA Congress since the global COVID-19 pandemic , and an important milestone in reconnecting with the European nephrology community. During the congress, our booth (X1.200) attracted considerable attention from both existing partners and new contacts. We were very encouraged by the many productive conversations and the strong interest shown by nephrology professionals across different regions. It was a great pleasure to meet some of our long-standing friends at the event, including: Stanningley Pharma (UK) — our valued distribution partner in the UK for more than 15 years Dr. Dan Heristea (France) — a nephrology expert and friend of FIRAPY Nordic MedCom (Nordic) — a familiar face from past interactions in the industry We were equally pleased to engage with potential new partners from Canada, Morocco, Panama, and the UAE . We look forward to the possibility of building new collaborations to further extend the clinical benefits of FIRAPY to more patients worldwide.  We sincerely thank everyone who visited our booth and supported us throughout the congress. We look forward to continuing these conversations and working together to advance vascular access care and patient outcomes through FIRAPY.

FIRAPY at ERA 2025 – See You in Vienna!

May 23, 2025
We’re excited to announce that FIRAPY will be exhibiting at the 62nd ERA Congress in Vienna from June 4–7, 2025 ! 📍 Booth No.: X1.200 📅 June 4–7, 2025 📍 Austria Center Vienna This marks FIRAPY’s first European event since the COVID-19 pandemic , making it a special occasion for us to reconnect with partners and professionals across the continent. This year’s congress theme, “Game Changers in Nephrology,” aligns perfectly with FIRAPY’s mission to enhance dialysis care through innovative vascular access management. We look forward to seeing old friends and new collaborators who share our commitment to improving outcomes for dialysis patients. Whether you're already using FIRAPY or exploring its clinical potential, we warmly invite you to visit our booth and connect with our team.  Let’s explore how far-infrared therapy is transforming the future of vascular access—together.

FIRAPY Joins Dialysis Weekend 2024 in Pattaya with K2 Thailand

May 23, 2025
From February 28 to March 1, FIRAPY was honored to participate in Dialysis Weekend 2024 in Pattaya, Thailand, at the invitation of our valued partner K2 Thailand . This annual event, hosted by the Nephrology Society of Thailand ( event site ), is a key gathering for nephrology professionals across the country. This occasion marked a milestone for K2 Thailand, as their entire dialysis sales team made their first collective public appearance alongside FIRAPY. The team’s strong presence and professionalism drew significant attention from both clinicians and industry attendees, highlighting the growing interest in FIRAPY's role in dialysis care. A special highlight of the event was the visit from Dr. Suki , a well-known figure in the international nephrology community ( WCN profile ). Dr. Suki stopped by the K2 booth to personally show support and encouragement to the team, reinforcing the collaboration and shared mission of improving vascular access outcomes for dialysis patients. 
More Posts